Old West Investment Management LLC Invests $7.15 Million in The Chemours Company $CC

Old West Investment Management LLC purchased a new stake in The Chemours Company (NYSE:CC) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 348,549 shares of the specialty chemicals company’s stock, valued at approximately $7,152,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cooper Creek Partners Management LLC purchased a new stake in Chemours during the third quarter worth about $63,103,000. Bank of New York Mellon Corp acquired a new position in Chemours during the second quarter worth about $33,353,000. Scopia Capital Management LP increased its holdings in Chemours by 71.7% in the second quarter. Scopia Capital Management LP now owns 3,355,261 shares of the specialty chemicals company’s stock valued at $38,418,000 after buying an additional 1,401,539 shares in the last quarter. State Street Corp increased its holdings in Chemours by 22.7% in the second quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company’s stock valued at $70,009,000 after buying an additional 1,131,682 shares in the last quarter. Finally, Sona Asset Management US LLC lifted its position in shares of Chemours by 176.9% during the 4th quarter. Sona Asset Management US LLC now owns 1,651,275 shares of the specialty chemicals company’s stock valued at $19,469,000 after acquiring an additional 1,055,000 shares during the period. Institutional investors and hedge funds own 76.26% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on CC shares. Royal Bank Of Canada decreased their price target on Chemours from $26.00 to $22.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Zacks Research downgraded Chemours from a “strong-buy” rating to a “strong sell” rating in a research note on Tuesday, August 11th. Alembic Global Advisors reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Chemours in a report on Wednesday, May 13th. The Goldman Sachs Group reiterated a “neutral” rating and set a $17.00 target price on shares of Chemours in a research report on Thursday. Finally, Morgan Stanley set a $18.00 target price on Chemours in a report on Monday, August 10th. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $20.10.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours is expanding its low-GWP Opteon refrigerant portfolio to address rising cooling demand from AI-driven data centers. The initiative could support growth in a higher-demand market while aligning with customers’ decarbonization goals. Zacks article on Chemours refrigerants for data centers
• Positive Sentiment: CEO Denise Dignam bought 3,378 shares for approximately $50,500, while insider Gerardo Familiar Calderon purchased 1,935 shares for roughly $30,000. The open-market purchases may suggest that insiders view the recent share-price weakness as an opportunity. SEC filing on CEO purchase SEC filing on insider purchase
• Neutral Sentiment: BMO Capital Markets cut its price target from $26 to $18 but maintained an “outperform” rating, leaving implied upside while signaling reduced expectations. The broader analyst consensus remains “hold,” with an average target near $20.10.
• Negative Sentiment: A securities-fraud investigation involving Chemours was announced, creating a potential legal and reputational overhang for shareholders. The announcement does not establish wrongdoing, but it may increase uncertainty around the company.
• Negative Sentiment: JPMorgan lowered its price target from $22 to $15 and kept a “neutral” rating, while Zacks Research downgraded the stock from “strong buy” to “strong sell.” These actions reinforce concerns following Chemours’ recent quarterly EPS and revenue misses. Benzinga report on JPMorgan target cut Zacks rating report

Insider Buying and Selling at Chemours

In related news, CEO Denise Dignam purchased 3,378 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was bought at an average cost of $14.95 per share, with a total value of $50,501.10. Following the completion of the acquisition, the chief executive officer directly owned 339,916 shares in the company, valued at $5,081,744.20. The trade was a 1.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Shane Hostetter acquired 3,350 shares of Chemours stock in a transaction dated Thursday, August 6th. The stock was bought at an average price of $14.94 per share, for a total transaction of $50,049.00. Following the completion of the transaction, the chief financial officer directly owned 102,698 shares of the company’s stock, valued at approximately $1,534,308.12. This represents a 3.37% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have purchased 8,663 shares of company stock worth $130,601. 0.85% of the stock is owned by insiders.

Chemours Stock Down 0.3%

Shares of NYSE CC opened at $15.81 on Monday. The Chemours Company has a 12-month low of $10.44 and a 12-month high of $28.67. The company has a market capitalization of $2.38 billion, a PE ratio of -8.28 and a beta of 1.43. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.66 and a quick ratio of 0.88. The firm’s 50-day moving average is $18.54 and its two-hundred day moving average is $20.03.

Chemours (NYSE:CC) last released its quarterly earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same quarter in the prior year, the company earned ($2.54) earnings per share. The firm’s revenue for the quarter was down 1.5% compared to the same quarter last year. Equities analysts anticipate that The Chemours Company will post 0.88 EPS for the current fiscal year.

Chemours Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 14th will be paid a $0.0875 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.35 dividend on an annualized basis and a yield of 2.2%. Chemours’s dividend payout ratio is presently -18.32%.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.